scholarly journals Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy

Cells ◽  
2019 ◽  
Vol 8 (7) ◽  
pp. 741 ◽  
Author(s):  
Dorsch ◽  
Schuldt ◽  
Remedios ◽  
Schinkel ◽  
Jong ◽  
...  
Keyword(s):  
Quality Control ◽  
Hypertrophic Cardiomyopathy ◽  
Protein Quality ◽  
Protein Quality Control ◽  
Left Ventricular ◽  
Microtubule Network ◽  
Protein Levels ◽  
Tubulin Acetylation ◽  
Genes Encoding ◽  
Sarcomere Proteins

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. It is mainly caused by mutations in genes encoding sarcomere proteins. Mutant forms of these highly abundant proteins likely stress the protein quality control (PQC) system of cardiomyocytes. The PQC system, together with a functional microtubule network, maintains proteostasis. We compared left ventricular (LV) tissue of nine donors (controls) with 38 sarcomere mutation-positive (HCMSMP) and 14 sarcomere mutation-negative (HCMSMN) patients to define HCM and mutation-specific changes in PQC. Mutations in HCMSMP result in poison polypeptides or reduced protein levels (haploinsufficiency, HI). The main findings were 1) several key PQC players were more abundant in HCM compared to controls, 2) after correction for sex and age, stabilizing heat shock protein (HSP)B1, and refolding, HSPD1 and HSPA2 were increased in HCMSMP compared to controls, 3) α-tubulin and acetylated α-tubulin levels were higher in HCM compared to controls, especially in HCMHI, 4) myosin-binding protein-C (cMyBP-C) levels were inversely correlated with α-tubulin, and 5) α-tubulin levels correlated with acetylated α-tubulin and HSPs. Overall, carrying a mutation affects PQC and α-tubulin acetylation. The haploinsufficiency of cMyBP-C may trigger HSPs and α-tubulin acetylation. Our study indicates that proliferation of the microtubular network may represent a novel pathomechanism in cMyBP-C haploinsufficiency-mediated HCM.

scholarly journals Protein quality control degron-containing substrates are differentially targeted in the cytoplasm and nucleus by ubiquitin ligases

Genetics ◽  
2020 ◽  
Vol 217 (1) ◽  
Author(s):  
Christopher M Hickey ◽  
Carolyn Breckel ◽  
Mengwen Zhang ◽  
William C Theune ◽  
Mark Hochstrasser
Keyword(s):  
Quality Control ◽  
Protein Quality ◽  
Protein Quality Control ◽  
Ubiquitin Ligases ◽  
Ubiquitin Proteasome System ◽  
Human Cells ◽  
Covalent Attachment ◽  
Protein Levels ◽  
Ubiquitin System ◽  
C Terminus

Abstract Intracellular proteolysis by the ubiquitin–proteasome system regulates numerous processes and contributes to protein quality control (PQC) in all eukaryotes. Covalent attachment of ubiquitin to other proteins is specified by the many ubiquitin ligases (E3s) expressed in cells. Here we determine the E3s in Saccharomyces cerevisiae that function in degradation of proteins bearing various PQC degradation signals (degrons). The E3 Ubr1 can function redundantly with several E3s, including nuclear-localized San1, endoplasmic reticulum/nuclear membrane-embedded Doa10, and chromatin-associated Slx5/Slx8. Notably, multiple degrons are targeted by more ubiquitylation pathways if directed to the nucleus. Degrons initially assigned as exclusive substrates of Doa10 were targeted by Doa10, San1, and Ubr1 when directed to the nucleus. By contrast, very short hydrophobic degrons—typical targets of San1—are shown here to be targeted by Ubr1 and/or San1, but not Doa10. Thus, distinct types of PQC substrates are differentially recognized by the ubiquitin system in a compartment-specific manner. In human cells, a representative short hydrophobic degron appended to the C-terminus of GFP-reduced protein levels compared with GFP alone, consistent with a recent study that found numerous natural hydrophobic C-termini of human proteins can act as degrons. We also report results of bioinformatic analyses of potential human C-terminal degrons, which reveal that most peptide substrates of Cullin-RING ligases (CRLs) are of low hydrophobicity, consistent with previous data showing CRLs target degrons with specific sequences. These studies expand our understanding of PQC in yeast and human cells, including the distinct but overlapping PQC E3 substrate specificity of the cytoplasm and nucleus.

scholarly journals Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy

2021 ◽  
Author(s):  
Roua Hassoun ◽  
Heidi Budde ◽  
Saltanat Zhazykbayeva ◽  
Melissa Herwig ◽  
Marcel Sieme ◽  
...  
Keyword(s):  
Quality Control ◽  
Hypertrophic Cardiomyopathy ◽  
Protein Quality ◽  
Protein Quality Control

Altered protein quality control in heart tissue of patients with hypertrophic cardiomyopathy

2018 ◽  
Vol 120 ◽  
pp. 11-12
Author(s):  
L.M. Dorsch ◽  
M. Schuldt ◽  
F.Z. Zitouny ◽  
R. Zaremba ◽  
C. dos Remedios ◽  
...  
Keyword(s):  
Quality Control ◽  
Hypertrophic Cardiomyopathy ◽  
Protein Quality ◽  
Protein Quality Control ◽  
Heart Tissue ◽  
Altered Protein

Abstract 131: PDE1 Inhibition Improves Cardiac Protein Quality Control

2016 ◽  
Vol 119 (suppl_1) ◽  
Author(s):  
Hanming Zhang ◽  
Xuejun "XJ" Wang
Keyword(s):  
Quality Control ◽  
Protein Quality ◽  
Protein Quality Control ◽  
Ubiquitin Proteasome System ◽  
Misfolded Proteins ◽  
Mrna Levels ◽  
Protein Levels ◽  
Ubiquitin Proteasome ◽  
Bona Fide

Protein quality control (PQC) functions to minimize the level and toxicity of misfolded proteins in the cell. PQC relies on molecular chaperones and the targeted degradation of misfolded proteins. The latter is currently known to require the ubiquitin-proteasome system (UPS) and the autophagic-lysosomal pathway (ALP). Virtually all cardiovascular diseases end up heart failure (HF), the leading cause of death of our society. UPS function insufficiency is implicated in the genesis of a large subset of HF, making cardiac PQC enhancement via promoting UPS and ALP function a promising therapeutic strategy to treat HF. Previously, we have demonstrated that stimulating protein kinase G (PKG) genetically or via inhibition of the type 5 phosphodiesterase (PDE5) improves UPS performance, facilitates the removal of misfolded proteins in cardiomyocytes and slows down the progression of cardiac proteinopathy in a transgenic mouse model (CryAB R120G ). PKA has also been shown to enhance proteasomal function. Our preliminary studies reveal that myocardial protein levels of PDE1A, which suppresses both PKG and PKA, are remarkably elevated in the CryAB R120G mice. Hence we hypothesize that PDE1 inhibition (PDE1I) stimulates cardiac proteasomes via PKG and PKA activation and thereby protects against cardiac proteotoxicity. To test our hypothesis, we took advantage of a proven surrogate UPS substrate (GFPu or GFPdgn) as well as a bona fide misfolded protein (CryAB R120G ) that is known to induce cardiac proteinopathy in human and mice. In cultured cardiomyocytes, PDE1 inhibitor LSN2790158 dose- and time-dependently decreased GFPu. Cycloheximide (CHX) chase assays further confirmed that PDE1I shortened the half-life of GFPu, indicative of improved UPS performance. Furthermore, PDE1I promoted the degradation of CryAB R120G . Our in vivo findings revealed that GFPdgn mice treated with LSN2790158 (3mg/kg, i.p.) displayed a significant reduction of myocardial GFPdgn protein but not mRNA levels. Taken together, our data strongly indicate that PDE1I improves cardiac UPS performance and PDE1 represents a potential target to treat cardiac diseases with elevated proteotoxicity.

Sign in / Sign up

Export Citation Format

Share Document